Journal of Clinical Oncology, Vol 6, 9-17, Copyright © 1988 by American Society of Clinical Oncology

ARTICLES

The benefit of adjuvant treatment for resected locally advanced non- small-cell lung cancer. The Lung Cancer Study Group

The purpose of this trial was to investigate the impact of systemic combination chemotherapy on survival and recurrence patterns in incompletely resected non-small-cell lung cancer. Incomplete resection was defined as presence of residual tumor in the resection margin or by presence of metastasis in the highest paratracheal lymph node sampled during protocol-directed surgical staging of the mediastinum. One hundred seventy-two patients were randomized to receive either postoperative radiotherapy (RT) alone or postoperative RT plus chemotherapy with CAP (Cytoxan [cyclophosphamide; Bristol Myers, Evansville, IN], Adriamycin [doxorubicin; Adria Laboratories, Columbus, OH], and Platinol [cisplatin; Bristol Myers]) for 6 months. One hundred sixty-four patients were eligible for analysis at a mean time since randomization of 3.7 years. The chemotherapy arm showed significantly longer recurrence-free survival (two-sided Mantel-Haenszel log rank test, P = .004). This difference holds true for nonsquamous patients (P = .01), and approaches significance for squamous patients as well (P = .08). There was a 14% difference in survival rate favoring the chemotherapy arm 1 year after randomization. Analysis of sites of recurrence showed a significant decrease in distant metastases in the chemotherapy arm. Median survival for the entire group was approximately 17 months, and 35% are alive 2 years after resection. Toxicity of treatment consisted of esophagitis (mild-moderate by Eastern Cooperative Oncology Group [ECOG] criteria) and predictable hematologic, gastrointestinal (GI), and skin toxicity expected from CAP.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. J. Wozniak and S. M. Gadgeel Review: Adjuvant therapy for resected non-small cell lung cancer Therapeutic Advances in Medical Oncology, September 1, 2009; 1(2): 109 - 118. [Abstract] [PDF]

				L. A. Robinson, J. C. Ruckdeschel, H. Wagner Jr, and C. W. Stevens Treatment of Non-small Cell Lung Cancer-Stage IIIA: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 243S - 265S. [Abstract] [Full Text] [PDF]

				F. Leo, N. Venissac, D. Pop, S. Khelef, and J. Mouroux How to Find the Limit Between Station 2 and Station 4 During Mediastinoscopy? Ann. Thorac. Surg., March 1, 2006; 81(3): 1150 - 1152. [Abstract] [Full Text] [PDF]

				Y. Sakao, H. Miyamoto, A. Yamazaki, T. Oh, R. Fukai, K. Shiomi, and Y. Saito Prognostic Significance of Metastasis to the Highest Mediastinal Lymph Node in Nonsmall Cell Lung Cancer Ann. Thorac. Surg., January 1, 2006; 81(1): 292 - 297. [Abstract] [Full Text] [PDF]

				A. L. Visbal, N. B. Leighl, R. Feld, and F. A. Shepherd Adjuvant Chemotherapy for Early-Stage Non-small Cell Lung Cancer Chest, October 1, 2005; 128(4): 2933 - 2943. [Abstract] [Full Text] [PDF]

				J. D. Bradley, R. Paulus, M. V. Graham, D. S. Ettinger, D. W. Johnstone, M. V. Pilepich, M. Machtay, R. Komaki, J. Atkins, and W. J. Curran Phase II Trial of Postoperative Adjuvant Paclitaxel/Carboplatin and Thoracic Radiotherapy in Resected Stage II and IIIA Non-Small-Cell Lung Cancer: Promising Long-Term Results of the Radiation Therapy Oncology Group--RTOG 9705 J. Clin. Oncol., May 20, 2005; 23(15): 3480 - 3487. [Abstract] [Full Text] [PDF]

				A. Spira and D. S. Ettinger Multidisciplinary Management of Lung Cancer N. Engl. J. Med., January 22, 2004; 350(4): 379 - 392. [Full Text] [PDF]

				S. G. Spiro and J. C. Porter Lung Cancer--Where Are We Today?: Current Advances in Staging and Nonsurgical Treatment Am. J. Respir. Crit. Care Med., November 1, 2002; 166(9): 1166 - 1196. [Abstract] [Full Text] [PDF]

				British Thoracic Society, Society of Cardiothoracic Surgeons of Great Britai, and Ireland Working Party Guidelines on the selection of patients with lung cancer for surgery Thorax, February 1, 2001; 56(2): 89 - 108. [Full Text]

				S. M. Keller, S. Adak, H. Wagner, A. Herskovic, R. Komaki, B. J. Brooks, M. C. Perry, R. B. Livingston, D. H. Johnson, and The Eastern Cooperative Oncology Group A Randomized Trial of Postoperative Adjuvant Therapy in Patients with Completely Resected Stage II or IIIa Non-Small-Cell Lung Cancer N. Engl. J. Med., October 26, 2000; 343(17): 1217 - 1222. [Abstract] [Full Text] [PDF]

				H. Asamura Complete resection: Yes or no? J. Thorac. Cardiovasc. Surg., January 1, 2000; 119(1): 193 - 194. [Full Text]

				D. G Altman and P. K. Andersen Calculating the number needed to treat for trials where the outcome is time to an event BMJ, December 4, 1999; 319(7223): 1492 - 1495. [Full Text]

				J. H. Lee, M. Machtay, L. R. Kaiser, J. S. Friedberg, S. M. Hahn, M. G. McKenna, and W. G. McKenna Non-Small Cell Lung Cancer: Prognostic Factors in Patients Treated with Surgery and Postoperative Radiation Therapy Radiology, December 1, 1999; 213(3): 845 - 852. [Abstract] [Full Text]

				G. M. Strauss Role of Chemotherapy in Stages I to III Non-small Cell Lung Cancer* Chest, December 1, 1999; 116 (2009): 509S - 516S. [Abstract] [Full Text] [PDF]

				J. R. Roberts, M. G. Blum, R. Arildsen, D. C. Drinkwater Jr, K. R. Christian, T. A. Powers, and W. H. Merrill Prospective comparison of radiologic, thoracoscopic, and pathologic staging in patients with early non-small cell lung cancer Ann. Thorac. Surg., October 1, 1999; 68(4): 1154 - 1158. [Abstract] [Full Text] [PDF]

				H. Wada, R. Miyahara, F. Tanaka, and S. Hitomi Postoperative adjuvant chemotherapy with PVM (Cisplatin+Vindesine+Mitomycin C) and UFT (Uracil+Tegaful) in resected stage I-II NSCLC (non-small cell lung cancer): a randomized clinical trial Eur. J. Cardiothorac. Surg., April 1, 1999; 15(4): 438 - 443. [Abstract] [Full Text] [PDF]

				S. George, M. J. Schell, F. C. Detterbeck, and M. A. Socinski Adjuvant Chemotherapy for Resected Non-Small Cell Carcinoma of the Lung: Why We Still Don't Know Oncologist, February 1, 1998; 3(1): 35 - 44. [Abstract] [Full Text]

				J. Olak and A. Ng Diagnosis and Treatment of Early-Stage Non-Small Cell Lung Cancer Oncologist, August 1, 1996; 1(4): 201 - 209. [Abstract] [Full Text] [PDF]

				Non-small Cell Lung Cancer Collaborative Group Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials BMJ, October 7, 1995; 311(7010): 899 - 909. [Abstract] [Full Text]

				A. Y. Lin and D. C. Ihde Recent Developments in the Treatment of Lung Cancer JAMA, March 25, 1992; 267(12): 1661 - 1664. [Abstract] [PDF]

				H. Stevenson, A. F. Gazdar, R. Phelps, R. I. Linnoila, D. C. Ihde, B. Ghosh, T. Walsh, E. L. Woods, H. Oie, T. O'Connor, et al. Tumor Cell Lines Established in Vitro: An Independent Prognostic Factor for Survival in Non-Small-Cell Lung Cancer Ann Intern Med, November 15, 1990; 113(10): 764 - 770. [Abstract] [PDF]